Other approaches focus directly on the kinase realm by generating kinase inhibitors targeting resistance-causing FLT3 point mutations [11], or by developing dual targeting compounds, which inhibit FLT3 and another kinase necessary for survival and proliferation of AML cells, for example, JAK2, MEK, MER, or CDK4 [12]. Here, CDK4 is linked to acute myeloid leukemia.